BioCentury
ARTICLE | Clinical News

ANG1005: Phase II started

June 9, 2014 7:00 AM UTC

Angiochem began an open-label, U.S. Phase II trial to evaluate ANG1005 in up to 40 patients with progressive or recurrent HER2-positive breast cancer with brain metastases. Late last month, FDA granted Orphan Drug and Fast Track designations to ANG1005 to treat glioblastoma multiforme (GBM). The product is also in Phase II testing for primary brain cancers, such as recurrent GBM and anaplastic glioma. ...